Stockwinners Market Radar for May 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

BRK.A...		Hot Stocks 20:13 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Berkshire Hathaway (BRK.A; BRK.B) reported a jump in its earnings for the first quarter due in part to a rebound in the insurance business. The company said operating earnings totaled $8.065B in Q1, up 12.6% from a year ago. Additionally, Berkshire said its cash hoard increased to $130.616B from $128B in the fourth quarter of 2022. The company repurchased $4.4B worth of stock, the most since Q1 2021 and up from $2.8B at the end of 2022. Berkshire's net earnings also increased to $35.5B in Q1 from $5.6B a year ago. 2. Volkswagen (VWAGY) is set to dismiss all but one of the executive board members at its software division Cariad next week to try to resolve development problems, Reuters' Jan Schwartz reports, citing a person familiar with the matter. The unit has exceeded its budget and failed to meet goals, contributing to Diess' departure and replacement by Oliver Blume last September, the author notes. Cariad's supervisory board is expected to sign off on the dismissals in a meeting next week, the source said on Saturday. 3. For weeks now, we've seen data pointing to continued struggles for all kinds of technology hardware. PC demand is tumbling. Smartphones are struggling to grow. It was a tough setup for Apple (AAPL). And yet the company delivered, Tae Kim writes in this week's edition of Barron's. In a world where most technology products are commodities, Apple's customers are less likely to be swayed by discounts. It has a stellar brand, high customer satisfaction, and incredible loyalty, the author notes. Apple shares aren't cheap. But Apple may be a relative haven compared with other big technology stocks. 4. Disney's (DIS) "Guardians of the Galaxy Vol. 3" won this weekend at the domestic box office with a $114M debut, making it the second-biggest opening weekend of the year behind "The Super Mario Bros. Movie" with $146M. Overseas, the conclusion to Marvel's trilogy of this crew of misfits opened to $168.1M for a global start of $282.1M. 5. Carrier (CARR), UnitedHealth Group (UNH), Conagra (CAG), Darling Ingredients (DAR) and Opal Fuels (OPAL) saw positive mentions in this week's edition of Barron's.
HSIC		Hot Stocks 18:21 EDT Henry Schein acquires Regional Health Care Group - Henry Schein announced on Sunday the acquisition of Regional Health Care Group, a medical products distribution company serving public- and private-sector customers in Australia and New Zealand. Henry Schein acquired RHCG, which had sales for the 12 months ended June 30, 2022, of $42M, from Maurie and Bernard Stang, who wholly owned the company and retain a minority interest in Henry Schein's ANZ dental business. Henry Schein expects the transaction to be neutral to 2023 diluted earnings per share when excluding amortization expenses and accretive thereafter. Financial terms were not disclosed.
EXEL		Hot Stocks 17:17 EDT Exelixis announces departure of Lance Willsey from Board of Directors - Exelixis announced that Lance Willsey has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10 director nominees and will not contest the election of Farallon Capital Management's additional nominee, David Johnson, at the upcoming 2023 Annual Meeting of Shareholders, to be held on May 31, 2023. As previously announced, the Board nominated two of Farallon's originally proposed candidates - Tomas Heyman and Robert Oliver - to replace two of its existing directors at the Annual Meeting. The Board is actively identifying, evaluating and interviewing candidates as part of its continued refreshment program, which includes a commitment to replacing two additional directors, one in each of the next two years, with two new independent directors. Following the upcoming Annual Meeting, five directors will have transitioned off the Board in the past three years, and four new independent directors will have been elected, including all of Farallon's nominees. The Board supports Willsey's decision, which will end the need for Farallon to continue its proxy campaign. Willsey's decision to resign is in connection with a personal matter that occurred more than a decade ago. The company engaged outside legal counsel at that time to review the matter and the Board at the time decided that no action was needed with respect to Willsey's Board representation.
SGHT		Hot Stocks 06:53 EDT Sight Sciences announces 12-month results from MIGS comparative analysis of RWD - Sight Sciences announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved Minimally Invasive Glaucoma Surgery, or MIGS, procedures in patients with mild stage glaucoma. Analysis included 16,789 patients in 4 different cohorts: procedures enabled by OMNI Surgical System technology in combination with cataract, iStent Inject in combination with cataract, Hydrus in combination with cataract or cataract surgery alone. Analysis of medical records of 16,789 mild glaucoma patients in the American Academy of Ophthalmology IRIS Registry -- Intelligent Research in Sight, one of the largest specialty society clinical data registries in all of medicine, showed that patients in the OMNI technology cohort experienced the greatest average medication reduction with a mean reduction from baseline of 1.01 glaucoma medications at 12 months post-operatively. This was a statistically significantly greater medication reduction when compared to the medication reductions observed for the iStent Inject in combination with cataract surgery as well as cataract surgery alone. The retrospective analysis was performed in partnership with Verana Health, the exclusive end-to-end data curation and analytics partner for the Academy's IRIS Registry. The collaboration between Sight Sciences and Verana Health reviewed real-world clinical outcomes data from MIGS devices and procedures within the IRIS Registry database from 2018-2020. The study's primary endpoint evaluated and compared IOP and medication reduction among FDA-approved or cleared MIGS used in combination with cataract surgery as well as cataract procedures alone at pre-specified time intervals up to 24 months.
BGNE		Hot Stocks 06:40 EDT BeiGene receives new approvals for BRUKINSA in China - BeiGene announced the China National Medical Products Administration, or NMPA, approved four applications for BRUKINSA, the company's Bruton's tyrosine kinase inhibitor, including two Supplemental New Drug Applications for treatment-naive adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenstrom's macroglobulinemia, and two Supplemental Applications for conversions from conditional approval to regular approval. BRUKINSA previously received conditional approvals from NMPA for the treatment of adult patients with CLL/SLL and mantle cell lymphoma who have received at least one prior therapy in June 2020, and conditional approval for the treatment of adult patients with WM who have received at least one prior therapy in June 2021. NMPA converted these conditional approvals to regular approvals for R/R CLL/SLL and R/R WM in April 2023. The new approvals of BRUKINSA for CLL/SLL are supported by data from SEQUOIA, in patients with previously untreated CLL/SLL. The new approvals of BRUKINSA for WM are based on data from ASPEN, the first and only global Phase 3 head-to-head clinical trial of BTK inhibitors in WM.
IMUX		Hot Stocks 06:25 EDT Immunic presents data for IMU-856 at Digestive Disease Week 2023 - Immunic announced the presentation of clinical and preclinical data for IMU-856. Included in this presentation are new data on IMU-856's mode of action as a potent modulator of SIRT6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining. In a preclinical DSS colitis model, IMU-856 treatment protected and also improved regeneration of the gut lining, as measured by normalization of crypt architecture. IMU-856 treatment also induced a dose-dependent tightening of the intestinal barrier, as measured by TEER, or transepithelial electrical resistance, assay. Gene expression experiments revealed that this latter effect can at least be partially attributed to the upregulation of barrier forming claudin-1 and the downregulation of channel forming claudin-2. Finally, data from Immunic's phase 1b clinical trial of IMU-856, summarized in the company's May 4, 2023 press release, also corroborated these findings in a proof-of-concept trial in celiac disease patients. Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption. The observed effects included, not only protecting the gut against effects of the gluten challenge, but also highlighted improvements in gut health which are relevant to celiac disease and to other gastrointestinal diseases. The consistent signals of IMU-856 treatment in this trial, as compared to placebo, seem to support clinical proof for the regeneration and renewal of the bowel wall.
PACW		Hot Stocks 06:21 EDT PacWest Bancorp declares quarterly cash dividend of 1c per common share - PacWest Bancorp announced that on May 3, 2023, its Board of Directors declared a quarterly cash dividend of 1c per common share. The cash dividend is payable on May 31, 2023 to stockholders of record at the close of business on May 15, 2023. On May 3, 2023, the Board of Directors also declared a quarterly cash dividend of $0.4845 per depositary share on its 7.75% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The dividend will be payable June 1, 2023 to stockholders of record as of May 15, 2023. Paul Taylor, President and CEO, commented, "Given current economic uncertainty, recent volatility in the banking sector and potential changes in regulatory capital requirements, we view reducing the dividend as a prudent step to accelerate our plans to build capital to CET1 of 10%+. Our business remains fundamentally sound, and we will continue with our strategy to focus on our relationship-based community banking model."